Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
about
Tacrolimus in preventing transplant rejection in Chinese patients--optimizing useImpact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipientsMycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events.The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part IInfluence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?Time-dependent clearance of mycophenolic acid in renal transplant recipientsImmunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome.Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritisIndividualization of mycophenolate mofetil dose in renal transplant recipients.Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability.Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.A limited sampling strategy for tacrolimus in renal transplant patientsKidney transplantation: current issues and future prospects.Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.Pharmacogenetic influences on mycophenolate therapy.Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation.A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation.Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation.Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials NetworkPharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.Tacrolimus prolonged release in kidney transplantation.Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics.Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†).Cyclosporin but not tacrolimus significantly increases salivary cytokine contents in rats.Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs.Therapeutic monitoring of mycophenolic acid: is there clinical utility?Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q28087131-9BD1F8E9-B359-4F25-91C9-DB60365392A9Q28538933-9276A0B4-329A-49CA-8487-B83E2FDC327BQ33370034-F4137DB1-AE00-4F58-A298-144366FB93C4Q33926957-A695EA12-418B-4D80-8650-C6A7DF13E1B5Q33944794-1D6CA5A8-3FC4-466B-8C9F-A62623CFC106Q34610933-D37EC85E-DB85-488E-B942-A506035A3EDAQ35619332-F34A3720-0A78-4A38-808F-95D280F10D79Q35823308-A5FF657F-7323-424B-9890-EAEF911132F5Q35848175-C5B3CEC9-0311-4BE4-B468-C89017C16852Q35980234-312549CC-FDAC-4125-B709-C597D35B2D7EQ36024478-204EFA7B-41FA-4836-A028-68C537EF0867Q36029868-D307D344-FBAA-4D7C-93B5-2975668FEF0BQ36243640-2E2F496B-BE97-46DE-BF3E-198496975BBEQ36407345-DBA18B05-BC2C-46DC-AF5A-3FB2964C1D71Q36544988-99911E16-9694-4741-BB3E-606EDAA49E51Q36788423-68B19424-8268-4AD9-9FB5-4785CEA75536Q36803391-3055E1C0-4FB1-4E13-9592-111764DD772BQ36922261-E1E5197C-9B2A-462C-9777-F40D9774ACA4Q36938148-393D79B7-599E-4737-A1E3-F0963FD3A770Q37013588-8219C44D-2A67-444F-A5D5-6728E326FC81Q37710509-5AF4EF06-8A04-4EED-BE47-0DC14CF08EA7Q38010596-F9892BCD-6958-4379-9234-F319E5AA94FBQ38087925-0CAFFCAE-DF57-416A-B086-17B324812820Q38170321-14C3CD50-2916-4662-A4E5-A299B0D033D8Q38223136-3BF6D206-B08D-4CF8-A59C-7C8B2C207869Q38520159-9C06D25B-88A0-4F8F-9FCA-0D59843C1D20Q39024541-A7F79C41-2DCE-4D97-A3CE-D4A4505F0A28Q41566058-4A299437-F3D5-4EFF-B9BF-BAD4E0DDF3A8Q42149848-8BA475FB-895D-4E7E-ADEB-73A1E7CC7E98Q42848628-6CE74F09-5CE2-42E0-9719-29A9BF579109Q43061696-A19FAABC-6EF6-42AF-8BB5-F9C8287CBB6CQ43253108-F11C8076-55CC-4454-9F81-E128701E411AQ45928212-F11A06E1-DD1C-40BF-8FA8-E19118B2B159Q46005342-8FE0F6E3-8069-41E5-960C-05E034DDD05DQ46710672-CCD50E84-EAA2-4F69-92E5-7441A8947469Q48133794-A9FBE8C2-C63A-4FA9-96A7-4ACA53A17A67Q51905914-2A888132-F272-4948-B96C-948F550F0BB2Q58805821-1660C258-05A9-448C-B74F-EBAD5598070E
P2860
Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Clinical efficacy and toxicity ...... vo renal allograft recipients.
@en
Clinical efficacy and toxicity ...... vo renal allograft recipients.
@nl
type
label
Clinical efficacy and toxicity ...... vo renal allograft recipients.
@en
Clinical efficacy and toxicity ...... vo renal allograft recipients.
@nl
prefLabel
Clinical efficacy and toxicity ...... vo renal allograft recipients.
@en
Clinical efficacy and toxicity ...... vo renal allograft recipients.
@nl
P2093
P1476
Clinical efficacy and toxicity ...... vo renal allograft recipients.
@en
P2093
Dirk R J Kuypers
Kathleen Claes
Pieter Evenepoel
Yves Vanrenterghem
P304
P356
10.1016/J.CLPT.2003.12.009
P407
P577
2004-05-01T00:00:00Z